Company Summary

Updated: August 12, 2007

Attribute Description
Lpath is the category leader in lipidomic-based therapeutics Lpath's Founder helped pioneer the bioactive lipid signaling space, which, according to an article in The British Journal of Cancer, is an emerging area of drug discovery. As such, we have deep and broad knowledge of lipids and how to work with them. Moreover, we have demonstrated a unique ability, using our ImmuneY2™ technology, to generate monoclonal antibodies against bioactive lipids, setting us apart from the rest of the field.
Powerful Pipeline Capability We used our proprietary ImmuneY2™ drug-discovery engine to develop the first monclonal antibodies ever developed against bioactive lysolipids. The first was Sphingomab™, whose systemic formulation is called ASONEP™ and whose ocular formulation is called iSONEP™; the second was Lpathomab™. With this ImmuneY2™ platform technology, we can continue to generate novel antibodies against other bioactive-lipid targets, thus creating a compelling pipeline of therapeutic candidates.
ASONEP™ might have several advantages over Avastin® A growing body of scientific literature demonstrates that S1P (ASONEP's target) is more angiogenic than VEGF (Avastin®'s target). In addition, we have an "Avastin®-like" effect in that ASONEP™ appears to significantly inhibit the functional activity of VEGF, Avastin®'s target. Finally, given that S1P is a lipid—and not a protein—cancerous tumors are less able to escape therapy by mutating around the target.
iSONEP™ might have several advantages over Lucentis® iSONEP™ appears to have additional mechanisms of action as compared with Lucentis®, including an anti-fibrotic effect (it is the fibrosis/scarring that produces irreversible vision loss in AMD patients). In addition, given that iSONEP™ has four times the molecular weight of Lucentis®, iSONEP™ might very well have a longer half life, resulting in fewer injections per year, a significant advantage.
Superior Intellectual Property Lpath has a total of over 26 issued or pending patents in the U.S. (with corresponding patent protection in Europe, Japan, etc.). Issued patent claims provide ownership of anti-sphingolipid therapeutic antibodies as compositions of matter; several patents issued and pending provide broad coverage of bioactive lipids as targets in the treatment of cancer, cardiovascular diseases, inflammation, autoimmune disorders, ocular disease and pathogenic angiogenesis. Because Lpath staked its intellectual property claims early, many of these issued and allowed patents may be considered dominating.
Experienced Executive & Advisory Team Roger Sabbadini, Ph.D., Founder and CSO: pioneer in bioactive lipid research, his lab has been studying the role of sphingolipid mediators in disease states for over 17 years.
Scott Pancoast, CEO: Harvard MBA, broad management/CEO experience; venture capitalist for 11 years with focus on biotechs.
Bill Garland, Ph.D., VP Development: 27 years in drug development with Roche and several start-ups.
Gary Atkinson, CFO: Over 20 years experience in corporate finance and accounting for public and private companies.
Geneviève Hansen, Ph.D., VP Research: broad experience with antibody research and development, with Novartis and Diversa.
Glenn Stoller, M.D., Head of Lpath Ocular: practicing retinal-eye surgeon; former advisor to Genentech and OSI/Eyetech.

We also utilize the services of several world-class consultants and SAB members with expertise in research, oncology, ophthalmology, inflammation, cardiology, diagnostics, therapeutics, and early-stage business development & execution.